Cipla FY24 Annual Earnings Summary

Cipla awaits US FDA classification for its Indore facility, which was audited in February 2023. This could impact approvals for key products like generic Advair.

Cipla's Goa facility is under remediation and expects re-inspection in H2 FY24. Any adverse outcome could disrupt supply of key products.

Indore facility received OAI from US FDA; corrective measures are ongoing but may delay US approvals.

Indore facility received a warning letter citing Albuterol complaints; resolution timeline uncertain and may impact future approvals.

Goa facility due for re-inspection; delay or adverse outcome could further delay Abraxane launch.

Patalganga received six 483 observations and Kurkumbh one; official classification awaited, potentially delaying product approvals.

Cipla faced an Albuterol recall in Q1 and experienced a market share decline in Q4 FY23, though management states share has stabilized.

While price erosion has eased, management noted it could revert to higher levels in later quarters, impacting US revenue sustainability.

Albuterol share is dependent on which variant the market buys; recovery to prior highs is not fully in Cipla's control.

Analyst questioned Revlimid volume trajectory after the initial 12-month period; management gave no specific guidance.

Pricing environment in US generics is in a downcycle; compression expected to move from 4-6% to 6-8% within a year.

Abraxane launch via third-party transfer is taking longer; fastest route is from Goa facility, which is subject to FDA inspection.